CA3137846A1 - Compositions and methods for personalized neoplasia vaccines - Google Patents

Compositions and methods for personalized neoplasia vaccines Download PDF

Info

Publication number
CA3137846A1
CA3137846A1 CA3137846A CA3137846A CA3137846A1 CA 3137846 A1 CA3137846 A1 CA 3137846A1 CA 3137846 A CA3137846 A CA 3137846A CA 3137846 A CA3137846 A CA 3137846A CA 3137846 A1 CA3137846 A1 CA 3137846A1
Authority
CA
Canada
Prior art keywords
neo
peptides
peptide
mutations
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3137846A
Other languages
English (en)
French (fr)
Inventor
Nir Hacohen
Catherine J. Wu
Edward F. Fritsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Dana Farber Cancer Institute Inc
Broad Institute Inc
Original Assignee
General Hospital Corp
Dana Farber Cancer Institute Inc
Broad Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Dana Farber Cancer Institute Inc, Broad Institute Inc filed Critical General Hospital Corp
Publication of CA3137846A1 publication Critical patent/CA3137846A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
CA3137846A 2013-04-07 2014-04-07 Compositions and methods for personalized neoplasia vaccines Pending CA3137846A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361809406P 2013-04-07 2013-04-07
US61/809,406 2013-04-07
US201361869721P 2013-08-25 2013-08-25
US61/869,721 2013-08-25
CA2908434A CA2908434C (en) 2013-04-07 2014-04-07 Compositions and methods for personalized neoplasia vaccines

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2908434A Division CA2908434C (en) 2013-04-07 2014-04-07 Compositions and methods for personalized neoplasia vaccines

Publications (1)

Publication Number Publication Date
CA3137846A1 true CA3137846A1 (en) 2014-10-16

Family

ID=50842334

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3137846A Pending CA3137846A1 (en) 2013-04-07 2014-04-07 Compositions and methods for personalized neoplasia vaccines
CA2908434A Active CA2908434C (en) 2013-04-07 2014-04-07 Compositions and methods for personalized neoplasia vaccines

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2908434A Active CA2908434C (en) 2013-04-07 2014-04-07 Compositions and methods for personalized neoplasia vaccines

Country Status (10)

Country Link
US (2) US20160101170A1 (enExample)
EP (1) EP2983702A2 (enExample)
JP (4) JP6702855B2 (enExample)
KR (3) KR102341899B1 (enExample)
CN (4) CN118750591A (enExample)
AU (5) AU2014251207B2 (enExample)
BR (1) BR112015025460B1 (enExample)
CA (2) CA3137846A1 (enExample)
IL (2) IL241858B (enExample)
WO (1) WO2014168874A2 (enExample)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
LT3892295T (lt) 2011-05-24 2023-07-10 BioNTech SE Individualizuotos vakcinos nuo vėžio
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
JP6484558B2 (ja) 2012-11-28 2019-03-13 バイオエヌテック エールエヌアー ファーマシューティカルズ ゲーエムベーハーＢｉｏｎｔｅｃｈ Ｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｇｍｂｈ 癌ワクチンの組み合せ物
BR112015025460B1 (pt) * 2013-04-07 2024-01-02 The Broad Institute, Inc. Método para a produção de uma vacina personalizada contra a neoplasia para um indivíduo diagnosticado como tendo uma neoplasia, vacina personalizada e uso da mesma
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) * 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CA2932798C (en) * 2013-12-06 2022-09-20 The Broad Institute, Inc. Formulations for neoplasia vaccines
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
WO2016040682A1 (en) 2014-09-10 2016-03-17 Genentech, Inc. Immunogenic mutant peptide screening platform
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
ES3049406T3 (en) 2014-12-19 2025-12-16 Broad Inst Inc Methods for profiling the t-cell-receptor repertoire
WO2016123365A1 (en) 2015-01-30 2016-08-04 The Regents Of The University Of Michigan Liposomal particles comprising biological molecules and uses thereof
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
CA2979388A1 (en) * 2015-03-12 2016-09-15 Health Research, Inc. Enrichment of cd16+ monocytes to improve dendritic cell vaccine quality
EP3273944B1 (en) 2015-03-25 2024-11-20 The Regents of The University of Michigan Compositions and methods for delivery of biomacromolecule agents
EP3075389A1 (en) * 2015-03-31 2016-10-05 Technische Universität München T cell receptors and peptides derived by mutations for the treatment of cancer
US20190099475A1 (en) 2015-04-08 2019-04-04 Nantomics, Llc Cancer neoepitopes
JP7236216B2 (ja) 2015-04-23 2023-03-09 ナントミクス，エルエルシー がんのネオエピトープ
EP3603665B1 (en) * 2015-04-27 2025-12-31 Cancer Research Technology Limited Personalized T-cell production methods for cancer treatment
AU2016258845B2 (en) * 2015-05-01 2022-03-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
SG10201912485PA (en) 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
CN108025048B (zh) 2015-05-20 2022-10-25 博德研究所 共有的新抗原
TWI750122B (zh) * 2015-06-09 2021-12-21 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
GB201516047D0 (en) * 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
KR20180087246A (ko) * 2015-10-12 2018-08-01 난토믹스, 엘엘씨 네오에피토프의 반복적 발견 및 이에 대한 적응성 면역치료 및 방법
CA3003302A1 (en) * 2015-10-12 2017-04-20 Nantomics, Llc Compositions and methods for viral cancer neoepitopes
WO2017066290A1 (en) * 2015-10-12 2017-04-20 Nantomics, Llc Viral neoepitopes and uses thereof
EP3362930A4 (en) 2015-10-12 2019-06-19 Nantomics, LLC SYSTEMS, COMPOSITIONS, AND METHODS FOR DISCOVERING MSI AND NEOEPPITOPES THAT PROVIDE SENSITIVITY TO IMMUNE CONTROL POINTS
TWI733719B (zh) 2015-12-07 2021-07-21 美商河谷控股Ｉｐ有限責任公司 改善的組合物及用於新表位之病毒遞送的方法及其應用
MX2018007204A (es) 2015-12-16 2018-12-11 Gritstone Oncology Inc Identificacion, fabricacion y uso de neoantigeno.
US20190022202A1 (en) 2016-01-08 2019-01-24 Vaccibody As Therapeutic anticancer neoepitope vaccine
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
US20190091316A1 (en) * 2016-02-11 2019-03-28 Nant Holdings Ip, Llc Subcutaneous Delivery of Adenovirus with Dual Targeting
US11361841B2 (en) * 2016-02-12 2022-06-14 Nantomics Llc High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies
CN109563521A (zh) 2016-03-24 2019-04-02 河谷细胞有限公司 用于新表位呈递的序列排列和序列
EP3446119A1 (en) * 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
WO2017192924A1 (en) 2016-05-04 2017-11-09 Fred Hutchinson Cancer Research Center Cell-based neoantigen vaccines and uses thereof
CN109641039B (zh) 2016-06-20 2023-08-04 Isa制药有限公司 肽疫苗制剂
US12257352B2 (en) 2016-06-20 2025-03-25 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
KR20230019223A (ko) * 2016-07-20 2023-02-07 비온테크 에스이 향상된 효능을 갖는 치료를 위한 질병-특이적 표적으로서 네오에피토프의 선택
US10350280B2 (en) 2016-08-31 2019-07-16 Medgenome Inc. Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
EP3535423B1 (en) * 2016-11-07 2022-01-05 The United States of America, as represented by the Secretary, Department of Health and Human Services Methods for selecting therapy for a cancer patient
AU2017363308B2 (en) * 2016-11-23 2024-08-08 Seattle Project Corp. Viral delivery of neoantigens
AU2017367696A1 (en) * 2016-12-01 2019-06-20 Nant Holdings Ip, Llc Tumor antigenicity processing and presentation
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CN110799196B (zh) * 2017-03-31 2024-02-13 行动基因(智财)有限公司 致免疫性的癌症特异抗原决定位的排名系统
WO2018183544A1 (en) * 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Method for identification of retained intron tumor neoantigens from patient transcriptome
AU2018254526B2 (en) * 2017-04-19 2024-02-15 Seattle Project Corp. Neoantigen identification, manufacture, and use
IL270132B2 (en) * 2017-04-24 2024-12-01 Nantcell Inc Neoepitope vectors and methods for them
MX2019013259A (es) 2017-05-08 2020-01-13 Gritstone Oncology Inc Vectores de neoantigeno de alfavirus.
US12226479B2 (en) 2017-05-11 2025-02-18 The General Hospital Corporation Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
US11484581B2 (en) 2017-06-02 2022-11-01 Arizona Board Of Regents On Behalf Of Arizona State University Method to create personalized canine cancer vaccines
KR102729393B1 (ko) * 2017-06-09 2024-11-13 그릿스톤 바이오, 인코포레이티드 신생항원 동정, 제조, 및 용도
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. RNA FORMULATIONS
WO2018234506A2 (en) * 2017-06-21 2018-12-27 Transgene Sa PERSONALIZED VACCINE
AU2018287169B2 (en) * 2017-06-22 2024-11-14 Neogap Therapeutics Ab T-cell expansion method and uses
WO2019014581A1 (en) 2017-07-14 2019-01-17 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
CN111315359A (zh) 2017-08-31 2020-06-19 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
IL273030B2 (en) * 2017-09-05 2024-03-01 Gritstone Bio Inc Neoantigen identification for t-cell therapy
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
WO2019060835A2 (en) 2017-09-25 2019-03-28 Nant Holdings Ip, Llc VALIDATION OF PRESENTATION OF NEO-EPITOPE
AU2018348165B2 (en) * 2017-10-10 2025-09-04 Seattle Project Corp. Neoantigen identification using hotspots
CA3081616A1 (en) * 2017-11-07 2019-05-16 Coimmune, Inc. Methods and uses for dendritic cell therapy
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
CN109865133B (zh) * 2017-12-01 2021-07-09 上海桀蒙生物技术有限公司 个性化癌症疫苗的制备方法
WO2019122050A1 (en) 2017-12-22 2019-06-27 Isa Pharmaceuticals B.V. Methods of immunization
CN108491689B (zh) * 2018-02-01 2019-07-09 杭州纽安津生物科技有限公司 基于转录组的肿瘤新抗原鉴定方法
AU2019261451A1 (en) 2018-04-26 2020-12-03 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
US20210361755A1 (en) * 2018-05-25 2021-11-25 The Wistar Institute Tumor-specific neoantigens and methods of using the same
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
JP2021529750A (ja) * 2018-06-27 2021-11-04 モデルナティーエックス， インコーポレイテッド 個別化がんワクチンエピトープの選択
WO2020020444A1 (en) * 2018-07-24 2020-01-30 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
WO2020022897A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
EP3846844A1 (en) * 2018-09-05 2021-07-14 Vaximm AG Neoantigen targeting dna vaccine for combination therapy
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
US12462898B2 (en) 2018-09-27 2025-11-04 Nykode Therapeutics ASA Method for selecting neoepitopes
CN109337873A (zh) * 2018-09-30 2019-02-15 北京鼎成肽源生物技术有限公司 一种lrff细胞
JP2022506839A (ja) * 2018-11-07 2022-01-17 モデルナティエックス インコーポレイテッド Ｒｎａがんワクチン
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
GB201821207D0 (en) 2018-12-24 2019-02-06 Tcer Ab Immunotherapy therapy
AU2020232971A1 (en) * 2019-03-01 2021-09-23 Scott R. BURKHOLZ Design, manufacture, and use of personalized cancer vaccines
EP3935638B1 (en) * 2019-03-08 2025-11-05 Nantomics, LLC System and method for variant calling
CN110059625B (zh) * 2019-04-18 2023-04-07 重庆大学 一种基于mixup的人脸训练与识别方法
EP4198513A1 (en) * 2019-05-03 2023-06-21 Epivax Therapeutics, Inc. Neoantigens in cancer
AU2020282369A1 (en) 2019-05-30 2022-01-20 Seattle Project Corp. Modified adenoviruses
EP3983008A4 (en) * 2019-06-11 2023-07-12 Iogenetics, LLC. IMMUNOTHERAPIES BASED ON NEO-ANTIGENS
EP3987028A4 (en) * 2019-06-21 2023-07-19 Kernal Biologics, Inc. MODIFIED ONCOSELECTIVE PROTEIN EXPRESSION
CN110514845B (zh) * 2019-08-22 2022-09-27 深圳新合睿恩生物医疗科技有限公司 一种肿瘤新生抗原免疫原性检测方法及检测平台
CN110464840A (zh) * 2019-09-06 2019-11-19 北京微九九科技有限公司 一种肿瘤疫苗的制备方法及使用该方法制备的肿瘤疫苗
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
WO2021092436A1 (en) * 2019-11-08 2021-05-14 The Regents Of The University Of California Identification of splicing-derived antigens for treating cancer
JP7496111B2 (ja) * 2019-12-24 2024-06-06 国立大学法人東京工業大学 サブキャリア変調方式テラヘルツレーダー
US11011253B1 (en) * 2020-07-09 2021-05-18 Brian Hie Escape profiling for therapeutic and vaccine development
CA3187258A1 (en) 2020-08-06 2022-02-10 Karin Jooss Multiepitope vaccine cassettes
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US20240024439A1 (en) * 2020-12-07 2024-01-25 Iogenetics, Llc Administration of anti-tumor vaccines
EP4255474A4 (en) * 2020-12-07 2025-06-18 Iogenetics, LLC. PERSONALIZED IMMUNOTHERAPIES
GB202104715D0 (en) 2021-04-01 2021-05-19 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
CN113069537A (zh) * 2021-04-29 2021-07-06 江苏欣生元生物科技有限公司 一种基于ras变异新生抗原表位的融合蛋白纳米疫苗及其制备方法
CA3214450A1 (en) 2021-04-30 2022-11-03 Tigen Pharma Sa Single vessel expansion of lymphocytes
CN112972666B (zh) * 2021-05-12 2021-08-31 山东兴瑞生物科技有限公司 个性化基因修饰肿瘤dc疫苗的制备方法
US20220383996A1 (en) * 2021-05-27 2022-12-01 Amazon Technologies, Inc. Assigning peptides to peptide groups for vaccine development
WO2023043888A1 (en) * 2021-09-15 2023-03-23 Celloram Inc. Method of treating cancer
TW202340474A (zh) 2022-01-11 2023-10-16 大陸商深圳市珈鈺生物科技有限公司 樹突細胞腫瘤疫苗和其用途
EP4522728A1 (en) * 2022-05-11 2025-03-19 Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud - Centro De Investigação Da Fundação Champalimaud Method of preparing and expanding a population of immune cells for cancer therapy, potency assay for tumor recognition, biological vaccine preparation and epitope target for antibodies
EP4598949A1 (en) 2022-10-07 2025-08-13 The General Hospital Corporation Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
AU2023372974A1 (en) 2022-11-02 2025-06-12 Centre Hospitalier Universitaire Vaudois (Chuv) Expansion of lymphocytes
WO2024261339A1 (en) 2023-06-23 2024-12-26 Tigen Pharma Sa Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines
CN120600110B (zh) * 2025-08-06 2025-12-09 上海交通大学医学院附属仁济医院 基于人工智能的多变病原t细胞表位精准筛选方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US4210644A (en) 1978-02-23 1980-07-01 The Johns Hopkins University Male contraception
US4226859A (en) 1979-06-07 1980-10-07 Velsicol Chemical Corporation Pyridyl esters of N-alkylidene-substituted phosphor- and phosphonamidic acids
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
ZA825384B (en) 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
DE3583799D1 (de) 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4743249A (en) 1986-02-14 1988-05-10 Ciba-Geigy Corp. Dermal and transdermal patches having a discontinuous pattern adhesive layer
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
US4906169A (en) 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US5023084A (en) 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4816540A (en) 1987-06-12 1989-03-28 Yasuhiko Onishi Cationic graft-copolymer
US5422119A (en) 1987-09-24 1995-06-06 Jencap Research Ltd. Transdermal hormone replacement therapy
US5035891A (en) 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US4973468A (en) 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
WO1991006309A1 (en) 1989-11-03 1991-05-16 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
US5198223A (en) 1990-10-29 1993-03-30 Alza Corporation Transdermal formulations, methods and devices
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5705190A (en) 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
KR100501022B1 (ko) 1998-07-28 2005-07-18 다나베 세이야꾸 가부시키가이샤 장내 적소 방출형 제제
US7220549B2 (en) 2004-12-30 2007-05-22 Helicos Biosciences Corporation Stabilizing a nucleic acid for nucleic acid sequencing
US7283337B2 (en) 2005-03-04 2007-10-16 Headway Technologies, Inc. Abutted exchange bias design for sensor stabilization
US20090186042A1 (en) * 2006-02-27 2009-07-23 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
CN101646455A (zh) * 2007-02-07 2010-02-10 财团法人阪大微生物病研究会 用于癌症的治疗剂
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
ES2608715T3 (es) * 2009-04-02 2017-04-12 Vaxon Biotech Identificación, optimización y uso de epítopos HLA-A24 crípticos para inmunoterapia
KR102017898B1 (ko) * 2010-05-14 2019-09-04 더 제너럴 하스피톨 코포레이션 종양 특이적 신생항원을 확인하는 조성물 및 방법
LT3892295T (lt) * 2011-05-24 2023-07-10 BioNTech SE Individualizuotos vakcinos nuo vėžio
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
EP2872653B1 (en) * 2012-07-12 2019-03-13 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
BR112015025460B1 (pt) * 2013-04-07 2024-01-02 The Broad Institute, Inc. Método para a produção de uma vacina personalizada contra a neoplasia para um indivíduo diagnosticado como tendo uma neoplasia, vacina personalizada e uso da mesma

Also Published As

Publication number Publication date
AU2021266338B2 (en) 2024-11-07
CN118750591A (zh) 2024-10-11
JP2022105069A (ja) 2022-07-12
KR20210156320A (ko) 2021-12-24
CA2908434C (en) 2021-12-28
WO2014168874A2 (en) 2014-10-16
AU2025200780A1 (en) 2025-02-27
AU2019203665B2 (en) 2021-03-11
CN105377292A (zh) 2016-03-02
JP7489193B2 (ja) 2024-05-23
IL241858B (en) 2021-04-29
WO2014168874A3 (en) 2014-12-18
CN118557711A (zh) 2024-08-30
CN117815373A (zh) 2024-04-05
BR112015025460A2 (pt) 2017-10-10
KR102858313B1 (ko) 2025-09-10
US20160101170A1 (en) 2016-04-14
NZ712933A (en) 2021-08-27
JP2020073553A (ja) 2020-05-14
KR102341899B1 (ko) 2021-12-21
US20210220455A1 (en) 2021-07-22
JP2025106390A (ja) 2025-07-15
IL282202B2 (en) 2025-11-01
EP2983702A2 (en) 2016-02-17
AU2021266338A1 (en) 2021-12-09
BR112015025460B1 (pt) 2024-01-02
AU2019203664B2 (en) 2021-08-12
CA2908434A1 (en) 2014-10-16
KR20150143597A (ko) 2015-12-23
JP2016518355A (ja) 2016-06-23
KR20230145545A (ko) 2023-10-17
IL282202A (en) 2021-05-31
JP6702855B2 (ja) 2020-06-03
IL282202B1 (en) 2025-07-01
AU2019203664A1 (en) 2019-06-13
AU2014251207B2 (en) 2019-06-13
AU2019203665A1 (en) 2019-06-13
AU2014251207A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
CA3137846A1 (en) Compositions and methods for personalized neoplasia vaccines
AU2020230277B2 (en) Combination therapy with neoantigen vaccine
JP7008049B2 (ja) 腫瘍特異的なネオ抗原を同定する組成物および方法
CA2932798C (en) Formulations for neoplasia vaccines
JP2022116237A (ja) ネオ抗原およびその使用方法
AU2016276704A1 (en) Formulations for neoplasia vaccines and methods of preparing them
CN112261947A (zh) 肿瘤特异性新抗原和其使用方法
NZ712933B2 (en) Compositions and methods for personalized neoplasia vaccines

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211105

EEER Examination request

Effective date: 20211105

EEER Examination request

Effective date: 20211105

EEER Examination request

Effective date: 20211105

EEER Examination request

Effective date: 20211105

EEER Examination request

Effective date: 20211105

EEER Examination request

Effective date: 20211105

EEER Examination request

Effective date: 20211105